리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 08월
페이지 정보:영문 284 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 히드록시진 시장은 2030년까지 6억 6,030만 달러에 달할 전망
2024년에 5억 1,680만 달러로 추정되는 세계의 히드록시진 시장은 2030년에는 6억 6,030만 달러에 달하며, 분석 기간인 2024-2030년의 CAGR은 4.2%로 성장할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 히스타민 개재성 소양증은 CAGR 4.6%를 기록하며, 분석 기간 종료시에는 3억 8,780만 달러에 달할 것으로 예측됩니다. 두드러기 적응증 부문의 성장률은 분석 기간 중 CAGR 3.2%로 추정됩니다.
미국 시장은 1억 4,080만 달러로 추정, 중국은 CAGR 7.7%로 성장할 것으로 예측
미국의 히드록시진 시장은 2024년에 1억 4,080만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 1억 3,560만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 7.7%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.7%와 3.3%로 예측됩니다. 유럽에서는 독일이 CAGR 2.4%로 성장할 것으로 예측됩니다.
세계의 히드록시진 시장 - 주요 동향과 촉진요인 정리
하이드록시 딘이 현대 치료 프로토콜에서 널리 처방되는 이유는 무엇인가?
하이드록시딘은 다양한 약리학적 프로파일로 인해 임상 의학의 다양한 분야에서 자주 사용되는 약물이 되었습니다. 원래 항히스타민제로 개발되었지만, 하이드록시딘은 그 용도를 넓혀 현재는 알레르기 반응뿐만 아니라 불안, 메스꺼움, 수면장애, 소양증 등에도 많이 처방되고 있습니다. H1 수용체 길항 작용과 중추신경 억제 작용을 동시에 가지고 있으며, 여러 계통에 걸친 증상 치료에 효과적입니다. 의사들은 불안과 흥분의 단기적 완화가 필요한 환자, 특히 약물 남용의 병력이 있고 기존의 항불안제 복용시 위험이 높은 환자에게 벤조디아제핀계 이외의 대안으로 하이드록시딘을 선택하는 경우가 많습니다. 또한 수술 전 불안감을 완화하고 가벼운 진정을 유도하기 위해 수술 전 설정에서도 일반적으로 처방됩니다. 피부과 영역에서 하이드록시딘은 항소양 작용과 만성 두드러기 및 피부염과 관련된 가려움증에 대처하는 능력으로 인해 지지받고 있습니다. 또한 구토 억제 작용으로 멀미, 화학요법이나 수술 후 회복과 관련된 메스꺼움의 치료에도 유용합니다. 하이드록시딘은 적응 범위가 넓고 중독 위험이 비교적 낮기 때문에 외래 및 입원 치료의 필수품이 되었습니다. 경구제와 근육내 투여제가 있으며, 치료의 긴급성과 환자의 경구 복용 능력에 따라 유연하게 대응할 수 있습니다. 소아과 의사와 노인 전문의 모두 하이드록시딘이 적절한 투여와 모니터링 하에 사용된다면 가치 있는 툴라는 것을 인정하고 있습니다. 의료 서비스 프로바이더들은 규제 약물의 복잡한 위험 프로파일 없이 여러 증상을 완화할 수 있는 약물을 찾고 있으며, 하이드록시딘은 치료 계획에서 매력적인 선택이 될 수 있습니다.
약리학적 특성과 안전성 프로파일이 임상적 유용성에 어떤 영향을 미치는가?
하이드록시딘의 약리학적 특성은 현재도 임상의들 사이에서 인기를 끌고 있는 데 중요한 역할을 하고 있습니다. 가장 두드러진 특징 중 하나는 혈액뇌관문을 통과하여 중추신경계 활동을 조절함으로써 진정 효과를 발휘하는 능력입니다. 하이드록시딘은 GABA 수용체에 직접 작용하는 기존의 진정제나 항불안제와 달리 히스타민 수용체를 길항하여 신경세포의 흥분성을 감소시킴으로써 진정 효과를 나타냅니다. 이 독특한 메커니즘을 통해 벤조디아제핀계 항불안제에서 흔히 발생하는 의존성 및 내성 문제 없이 항불안 및 진정 작용을 발휘합니다. 이 약은 작용 발현이 빠르며, 보통 경구 투여 후 15-30분 이내에 효과가 나타나기 때문에 급성 불안증상이나 알레르기 반응에 특히 유용합니다. 하이드록시 딘은 일반적으로 내약성이 좋지만, 특히 간 또는 신장 장애가있는 환자에서는 본 약물이 간에서 대사되고 신장으로 배설되므로 특정 예방 조치가 필요합니다. 졸음, 구강건조, 어지러움, 때로는 눈의 침침함 등의 부작용이 흔히 나타나지만, 일반적으로 경미하고 일시적인 증상입니다. 중요한 것은 하이드록시딘은 다른 진정제만큼 인지기능이나 운동기능을 방해하지 않기 때문에 상대적으로 주의력을 유지해야 하는 환자에게 더 안전한 선택이 될 수 있다는 점입니다. 고용량 또는 다른 약물과 병용시 QT 간격이 연장될 수 있으므로, 심장질환이 있는 환자에게는 심장 모니터링이 권장될 수 있습니다. 습관성이 없기 때문에 만성적인 증상 관리가 필요한 장기 요양 환경에서 그 가치가 높아집니다. 전반적으로 하이드록시딘의 확립된 안전성 프로파일, 광범위한 작용 스펙트럼, 그리고 상대적으로 저렴한 가격은 현대 임상에서 하이드록시딘의 지속적인 관련성에 기여하고 있습니다.
세계 헬스케어에서 어떤 치료 동향이 하이드록시딘 수요를 형성하고 있는가?
정신건강에 대한 인식, 만성질환 관리, 다증상 치료의 세계적인 추세는 모두 하이드록시딘에 대한 지속적인 수요에 기여하고 있습니다. 사회적 스트레스, 경제적 불안정, 팬데믹 이후 정신건강 문제로 인해 불안장애의 유병률이 증가함에 따라 많은 의료 서비스 프로바이더들은 다양한 사람들의 증상을 관리하기 위해 즉각적이고 의존성이 없는 대안을 찾고 있습니다. 하이드록시딘은 이러한 요구에 부합하며, 오남용 우려가 적은 증상 완화제를 제공합니다. 동시에 비염, 습진, 두드러기 등 알레르기 관련 증상은 특히 오염도가 높은 도시 환경에서 증가하는 추세입니다. 하이드록시딘의 항히스타민 작용은 알레르기 증상 조절과 그에 따른 불안 및 불면증 완화가 필요한 환자에게 적합한 선택이 될 수 있습니다. 종양학 및 완화 치료에서 하이드록시딘은 메스꺼움, 구토 및 일반적인 불편감을 관리하기 위한 지지요법 프로토콜에 점점 더 많이 도입되고 있습니다. 하이드록시딘은 신체적, 심리적 증상 완화에 유용하며, 다학제적 치료 계획에서 그 가치를 높이고 있습니다. 또한 하이드록시딘의 적응증 외 사용으로 치매 및 발달 장애 환자의 흥분 및 과민 반응과 같은 특정 행동 증상의 치료가 보편화되고 있습니다. 또한 맞춤형 의료와 통합의학으로의 전환이 증가함에 따라 임상의들은 단일 화합물로 여러 증상에 대응할 수 있는 약물을 채택하여 폴리파머시 위험을 최소화하고 있습니다. 의료 시스템이 비용 효율적이고 광범위한 스펙트럼의 약물에 초점을 맞추고 있으므로 하이드록시 딘은 포뮬러의 대상으로서 매력적입니다. 첨단 정신과 및 피부과 치료제에 대한 접근성이 제한되어 있는 많은 신흥 국가에서 하이드록시딘은 신뢰할 수 있고 저렴한 가격의 1차 선택 약물로 활용되고 있습니다. 이러한 폭넓은 치료 동향은 전문 의료 및 1차 의료 분야에서 하이드록시딘의 핵심 약물로서의 입지를 확고히 하고 있습니다.
세계 하이드록시 딘 시장의 지속적인 성장 요인은 무엇인가?
세계 하이드록시딘 시장은 임상적 유용성, 저렴한 가격, 규제 당국의 지원, 선진국과 신흥 시장 모두에서 헬스케어 수요 증가로 인해 성장하고 있습니다. 주요 촉진요인 중 하나는 전 세계에서 정신질환과 알레르기 질환의 부담이 증가함에 따라 신속하고 안전한 치료 옵션이 필요하게 되었습니다는 점입니다. 하이드록시딘은 다면적인 적용이 가능하므로 환자가 중복된 증상을 보이는 복잡한 환자를 관리하는 의사들 사이에서 지지를 받고 있습니다. 하이드록시딘은 특히 제네릭 의약품으로 가격이 저렴하므로 공중 보건 시스템이나 자원이 부족한 환경에서 쉽게 이용할 수 있는 치료 옵션입니다. 또한 하이드록시 딘은 많은 국가의 규제 당국에 의해 널리 승인되어 정부 운영 의료 프로그램 및 민간 제공 업체를 통해 쉽게 배포 할 수 있습니다. 제약사들은 진화하는 소비자의 선호도와 임상적 니즈에 대응하기 위해 서방형 버전과 병용요법을 포함한 새로운 제형에 대한 투자를 지속하고 있습니다. 원격의료와 디지털 처방 플랫폼의 부상도 한몫을 하고 있으며, 하이드록시딘과 같이 널리 이해되고 안전성이 높은 약물이 원격 처방에 자주 선택되고 있습니다. 병원이나 외래 진료소에서는 하이드록시딘의 효과를 예측할 수 있고 다른 치료법과의 궁합이 좋기 때문에 치료 프로토콜에 하이드록시딘을 채택하는 경우가 늘고 있습니다. 다발성 경화증 위험이 높은 소아과 및 노인 의료에서 하이드록시딘의 단일제 효능은 중요한 이점이 되고 있습니다. 정신건강 치료와 관련된 낙인을 줄이기 위한 교육 구상에 힘입어 시장 성장은 더욱 가속화되고 있으며, 그 결과 더 많은 사람들이 불안, 불면증 및 관련 증상에 대한 의학적 도움을 구하고 있습니다. 이러한 요인으로 인해 하이드록시딘은 전 세계에서 안정적인 수요와 시장 침투가 지속되고 있으며, 종합적이고 접근이 용이하며 비용 효율적인 약리학적 솔루션에 대한 요구가 증가함에 따라 의료 시스템이 적응함에 따라 지속적으로 확대될 것으로 예측됩니다.
우리는 검증된 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.
Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
목차
제1장 조사 방법
제2장 개요
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
KSA
영문 목차
영문목차
Global Hydroxyzine Market to Reach US$660.3 Million by 2030
The global market for Hydroxyzine estimated at US$516.8 Million in the year 2024, is expected to reach US$660.3 Million by 2030, growing at a CAGR of 4.2% over the analysis period 2024-2030. Histamine-Mediated Pruritus Indication, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$387.8 Million by the end of the analysis period. Growth in the Urticaria Indication segment is estimated at 3.2% CAGR over the analysis period.
The U.S. Market is Estimated at US$140.8 Million While China is Forecast to Grow at 7.7% CAGR
The Hydroxyzine market in the U.S. is estimated at US$140.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$135.6 Million by the year 2030 trailing a CAGR of 7.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.
Global Hydroxyzine Market - Key Trends and Drivers Summarized
Why Is Hydroxyzine a Widely Prescribed Medication in Modern Therapeutic Protocols?
Hydroxyzine has become a frequently utilized medication across various branches of clinical medicine due to its versatile pharmacological profile. Originally developed as an antihistamine, hydroxyzine has expanded in application and is now commonly prescribed not only for allergic reactions but also for anxiety, nausea, sleep disturbances, and pruritus. Its dual action as both an H1 receptor antagonist and a central nervous system depressant allows it to be effective in treating symptoms across multiple systems. Physicians often turn to hydroxyzine as a non-benzodiazepine alternative for patients who require short-term relief from anxiety or agitation, particularly those with a history of substance abuse where traditional anxiolytics may pose a higher risk. It is also commonly prescribed in preoperative settings to ease anxiety and produce mild sedation. In dermatology, hydroxyzine is favored for its antipruritic effects and ability to manage chronic urticaria and dermatitis-related itch. Furthermore, the medication’s antiemetic properties make it useful for treating motion sickness and nausea related to chemotherapy or postoperative recovery. The wide range of indications and relatively low risk of addiction has made hydroxyzine a staple in outpatient and inpatient care settings alike. Its oral and intramuscular formulations offer flexibility depending on the urgency of treatment or the patient’s ability to take medications orally. Pediatricians and geriatric specialists alike find hydroxyzine to be a valuable tool, provided it is used with appropriate dosing and monitoring. As healthcare providers increasingly look for medications that offer multi-symptom relief without the complex risk profiles of controlled substances, hydroxyzine remains an appealing choice in therapeutic planning.
How Do Pharmacological Properties and Safety Profiles Influence Its Clinical Utility?
The pharmacological characteristics of hydroxyzine play a significant role in its ongoing popularity among clinicians. One of its most notable features is its ability to cross the blood-brain barrier and exert calming effects through modulation of activity in the central nervous system. Unlike traditional sedatives or anxiolytics that directly affect GABA receptors, hydroxyzine exerts its calming influence by antagonizing histamine receptors and reducing neuronal excitability. This unique mechanism allows it to deliver anxiolytic and sedative effects without the typical dependence and tolerance issues that often accompany benzodiazepines. The drug has a rapid onset of action, typically taking effect within 15 to 30 minutes after oral administration, which is particularly useful in acute anxiety episodes or allergic reactions. While hydroxyzine is generally well tolerated, certain precautions are necessary, especially in patients with liver or kidney impairment, since the drug is metabolized hepatically and excreted renally. Side effects such as drowsiness, dry mouth, dizziness, and occasionally blurred vision are common but typically mild and transient. Importantly, hydroxyzine does not interfere with cognitive or motor functions to the same extent as other sedatives, making it a safer option for individuals who must remain relatively alert. Cardiac monitoring may be advised in patients with known heart conditions due to the potential for QT interval prolongation in high doses or when combined with other medications. Its non-habit-forming nature adds to its value in long-term care environments where chronic symptom management is necessary. Overall, hydroxyzine's well-established safety profile, broad spectrum of action, and relatively low cost contribute to its enduring relevance in modern clinical practice.
What Therapeutic Trends Are Shaping the Demand for Hydroxyzine in Global Healthcare?
Global trends in mental health awareness, chronic disease management, and multi-symptom therapy are all contributing to sustained demand for hydroxyzine. The increasing prevalence of anxiety disorders, driven by societal stress, economic instability, and post-pandemic mental health challenges, has led many healthcare providers to seek fast-acting, non-addictive alternatives to manage symptoms in diverse populations. Hydroxyzine fits this requirement, offering symptomatic relief with fewer concerns about misuse. At the same time, allergy-related conditions such as rhinitis, eczema, and hives are on the rise, particularly in urban environments with high pollution levels. The antihistamine properties of hydroxyzine make it a suitable option for patients requiring both allergic symptom control and relief from associated anxiety or insomnia. In oncology and palliative care settings, hydroxyzine is increasingly incorporated into supportive care protocols to manage nausea, vomiting, and general discomfort. Its dual utility in both physical and psychological symptom relief enhances its value in multidisciplinary treatment plans. Additionally, hydroxyzine’s off-label use in treating certain behavioral symptoms, including agitation and irritability in patients with dementia or developmental disorders, is becoming more common. The growing shift toward personalized and integrative medicine is also pushing clinicians to adopt medications that address multiple symptoms with a single compound, minimizing polypharmacy risks. With healthcare systems focusing on cost-effective, broad-spectrum medications, hydroxyzine remains attractive for formulary inclusion. In many developing countries, where access to advanced psychiatric or dermatologic drugs may be limited, hydroxyzine serves as a reliable and affordable first-line option. These broader therapeutic trends are helping solidify its position as a core medication in both specialty and primary care environments.
What Factors Are Contributing to the Continued Growth of the Hydroxyzine Market Globally?
The global hydroxyzine market is expanding due to a combination of clinical utility, affordability, regulatory support, and increasing healthcare demands across both developed and emerging markets. One major driver is the growing global burden of mental health conditions and allergic diseases, which require versatile treatment options that can be deployed quickly and safely. Hydroxyzine, with its multifaceted applications, has gained favor among practitioners who manage complex cases where patients present with overlapping symptoms. The affordability of hydroxyzine, particularly in its generic forms, makes it an accessible treatment option in public health systems and low-resource settings. Additionally, the widespread approval of hydroxyzine by regulatory bodies in numerous countries facilitates its distribution through both government-run healthcare programs and private providers. Pharmaceutical companies are continuing to invest in new formulations, including extended-release versions and combination therapies, to cater to evolving consumer preferences and clinical needs. The rise in telemedicine and digital prescribing platforms has also played a role, as medications like hydroxyzine that are widely understood and have a strong safety record are frequently chosen for remote prescriptions. Hospitals and outpatient clinics increasingly favor hydroxyzine in treatment protocols because of its predictable effects and compatibility with other therapies. In pediatric and geriatric care, where polypharmacy risks are higher, hydroxyzine’s single-agent efficacy is a key advantage. Market growth is further supported by educational initiatives aimed at reducing the stigma associated with mental health treatment, which in turn is encouraging more individuals to seek medical support for anxiety, insomnia, and related conditions. As a result of these factors, hydroxyzine continues to see steady demand and market penetration globally, with prospects for sustained expansion as healthcare systems adapt to the rising need for comprehensive, accessible, and cost-effective pharmacological solutions.
SCOPE OF STUDY:
The report analyzes the Hydroxyzine market in terms of units by the following Segments, and Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 44 Featured) -
Amneal Pharmaceuticals, Inc.
Apotex Inc.
Aurobindo Pharma Ltd.
Cadila Pharmaceuticals Ltd.
Cipla Ltd.
Dr. Reddy's Laboratories Ltd.
Endo International plc
Hikma Pharmaceuticals PLC
Jubilant Pharmova Ltd.
Lupin Limited
Mylan N.V. (Viatris)
Perrigo Company plc
Pfizer Inc.
Sandoz (a Novartis division)
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Torrent Pharmaceuticals Ltd.
Unichem Laboratories Ltd.
Zydus Lifesciences Ltd.
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Tariff Impact on Global Supply Chain Patterns
Hydroxyzine - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Prevalence of Anxiety and Allergic Conditions Throws the Spotlight on Hydroxyzine as a Versatile Therapeutic Agent
Increased Preference for Non-Benzodiazepine Anxiolytics Propels Growth in Hydroxyzine Prescriptions
Here's the Story: Expanding Off-Label Use in Sleep Disorders and Itching Strengthens the Business Case for Hydroxyzine
Growing Demand for Pediatric Allergy Treatments Drives Adoption in Liquid and Syrup Formulations
Cost-Effective Generic Availability Sustains Widespread Use Across Primary Care and Psychiatry Settings
Integration into Multimodal Treatment Plans Enhances Demand in Dermatology and Palliative Care
Rising Incidence of Urticaria and Atopic Dermatitis Expands Addressable Market for Antihistamine-Based Therapies
Preference for Sedating Antihistamines in Acute Episodes Fuels Short-Term Use Cases for Hydroxyzine
Global Generic Drug Expansion and Local Manufacturing Capabilities Drive Accessibility in Emerging Markets
Formulation Innovations and Extended-Release Research Open Future Opportunities in Dosing Convenience
Telehealth and E-Prescription Models Support Continued Market Presence in Remote and Mental Health Care Settings
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Hydroxyzine Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Hydroxyzine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Hydroxyzine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 4: World 16-Year Perspective for Hydroxyzine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Histamine-Mediated Pruritus Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Histamine-Mediated Pruritus Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 7: World 16-Year Perspective for Histamine-Mediated Pruritus Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Urticaria Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Urticaria Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 10: World 16-Year Perspective for Urticaria Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Atopic Contact Dermatitis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Atopic Contact Dermatitis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 13: World 16-Year Perspective for Atopic Contact Dermatitis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Tablets Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Tablets Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 16: World 16-Year Perspective for Tablets Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Capsules Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Capsules Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 19: World 16-Year Perspective for Capsules Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Injection Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Injection Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 22: World 16-Year Perspective for Injection Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Syrup Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Syrup Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 25: World 16-Year Perspective for Syrup Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 26: USA Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 27: USA Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 28: USA 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 29: USA Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 30: USA Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 31: USA 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
CANADA
TABLE 32: Canada Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 33: Canada Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 34: Canada 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 35: Canada Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 37: Canada 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
JAPAN
Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 38: Japan Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 39: Japan Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 40: Japan 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 41: Japan Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 43: Japan 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
CHINA
Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 44: China Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 45: China Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 46: China 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 47: China Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 48: China Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 49: China 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
EUROPE
Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 50: Europe Recent Past, Current & Future Analysis for Hydroxyzine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 51: Europe Historic Review for Hydroxyzine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 52: Europe 16-Year Perspective for Hydroxyzine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
TABLE 53: Europe Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 55: Europe 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 58: Europe 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
FRANCE
Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 59: France Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 60: France Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 61: France 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 62: France Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 63: France Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 64: France 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
GERMANY
Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 65: Germany Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 66: Germany Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 67: Germany 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 68: Germany Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 70: Germany 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
ITALY
TABLE 71: Italy Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 72: Italy Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 73: Italy 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 74: Italy Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 76: Italy 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
UNITED KINGDOM
Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 77: UK Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 78: UK Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 79: UK 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 80: UK Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 81: UK Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 82: UK 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
SPAIN
TABLE 83: Spain Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 84: Spain Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 85: Spain 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 86: Spain Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 87: Spain Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 88: Spain 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
RUSSIA
TABLE 89: Russia Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 90: Russia Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 91: Russia 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 92: Russia Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 93: Russia Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 94: Russia 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
REST OF EUROPE
TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 96: Rest of Europe Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 97: Rest of Europe 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 100: Rest of Europe 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
ASIA-PACIFIC
Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Hydroxyzine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 102: Asia-Pacific Historic Review for Hydroxyzine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 103: Asia-Pacific 16-Year Perspective for Hydroxyzine by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 106: Asia-Pacific 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 109: Asia-Pacific 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
AUSTRALIA
Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 110: Australia Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 111: Australia Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 112: Australia 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 113: Australia Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 114: Australia Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 115: Australia 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
INDIA
Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 116: India Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 117: India Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 118: India 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 119: India Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 120: India Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 121: India 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
SOUTH KOREA
TABLE 122: South Korea Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 123: South Korea Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 124: South Korea 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 125: South Korea Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 126: South Korea Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 127: South Korea 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 129: Rest of Asia-Pacific Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 132: Rest of Asia-Pacific Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
LATIN AMERICA
Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 134: Latin America Recent Past, Current & Future Analysis for Hydroxyzine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 135: Latin America Historic Review for Hydroxyzine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 136: Latin America 16-Year Perspective for Hydroxyzine by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
TABLE 137: Latin America Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 139: Latin America 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 140: Latin America Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 142: Latin America 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
ARGENTINA
TABLE 143: Argentina Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 144: Argentina Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 145: Argentina 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 146: Argentina Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 147: Argentina Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 148: Argentina 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
BRAZIL
TABLE 149: Brazil Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 150: Brazil Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 151: Brazil 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 152: Brazil Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 153: Brazil Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 154: Brazil 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
MEXICO
TABLE 155: Mexico Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 156: Mexico Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 157: Mexico 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 158: Mexico Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 159: Mexico Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 160: Mexico 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
REST OF LATIN AMERICA
TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 162: Rest of Latin America Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 163: Rest of Latin America 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 165: Rest of Latin America Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 166: Rest of Latin America 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
MIDDLE EAST
Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 167: Middle East Recent Past, Current & Future Analysis for Hydroxyzine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 168: Middle East Historic Review for Hydroxyzine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 169: Middle East 16-Year Perspective for Hydroxyzine by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
TABLE 170: Middle East Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 172: Middle East 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 173: Middle East Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 175: Middle East 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
IRAN
TABLE 176: Iran Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 177: Iran Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 178: Iran 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 179: Iran Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 180: Iran Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 181: Iran 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
ISRAEL
TABLE 182: Israel Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 183: Israel Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 184: Israel 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 185: Israel Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 186: Israel Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 187: Israel 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
SAUDI ARABIA
TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 189: Saudi Arabia Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 190: Saudi Arabia 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 192: Saudi Arabia Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 193: Saudi Arabia 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 194: UAE Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 195: UAE Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 196: UAE 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 197: UAE Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 198: UAE Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 199: UAE 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
REST OF MIDDLE EAST
TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 201: Rest of Middle East Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 202: Rest of Middle East 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 204: Rest of Middle East Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 205: Rest of Middle East 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
AFRICA
Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 206: Africa Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 207: Africa Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 208: Africa 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
TABLE 209: Africa Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 210: Africa Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 211: Africa 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030